Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort

ConclusionThis is the first report of “real-world” data on ICI in relapsed SCLC also including patients with poor PS. Promising durable responses were observed. No biological prognostic marker could be identified.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research